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Abstract 
 
The peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) enhances oxidative 
metabolism in skeletal muscle. Excessive lipid oxidation and electron transport chain activity 
can, however, lead to the accumulation of harmful metabolites and impair glucose 
homeostasis. Here, we investigated the effect of over-expression of PGC-1α on metabolic 
control and generation of insulin desensitizing agents in extensor digitorum longus (EDL), a 
muscle that exhibits low levels of PGC-1α in the untrained state and minimally relies on 
oxidative metabolism. We demonstrate that PGC-1α induces a strictly balanced substrate 
oxidation in EDL by concomitantly promoting the transcription of activators and inhibitors of 
lipid oxidation. Moreover, we show that PGC-1α enhances the potential to uncouple oxidative 
phosphorylation. Thereby, PGC-1α boosts elevated, yet tightly regulated oxidative 
metabolism devoid of side products that are detrimental for glucose homeostasis. 
Accordingly, PI3K activity, an early phase marker for insulin resistance, is preserved in EDL 
muscle. Our findings suggest that PGC-1α coordinately coactivates the simultaneous 
transcription of gene clusters implicated in the positive and negative regulation of oxidative 
metabolism and thereby increases metabolic flexibility. Thus, in mice fed a normal chow diet, 
over-expression of PGC-1α does not alter insulin sensitivity and the metabolic adaptations 
elicited by PGC-1α mimic the beneficial effects of endurance training on muscle metabolism 
in this context. 
 
Key words: metabolic flexibility, exercise mimetics, insulin resistance, glucose homeostasis, 
PGC-1α 
 
Highlights 
 
>PGC-1α enhances muscle oxidative capacity>PGC-1α promotes concomitantly positive and 
negative regulators of lipid oxidation>Regulator abundance enhances metabolic flexibility 
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and balances oxidative metabolism>Balanced oxidation prevents detrimental acylcarnitine 
and ROS generation>Absence of detrimental metabolites preserves insulin sensitivity 
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Introduction 
 
The increasing prevalence of metabolic disorders in our modern society represents a serious 
medical and economic challenge for the future [1]. A sedentary lifestyle and a low metabolic 
efficiency substantially contribute to the development of such diseases [1; 2]. Inversely, 
regular exercise ameliorates or partially prevents these conditions. 
 
The peroxisome proliferator-activated receptor γ coactivator 1α largely mediates the adaptive 
effects of exercise in skeletal muscle [3; 4; 5]. PGC-1α is a transcriptional coactivator and is 
known to promote the expression of several transcription factors, which it subsequently 
coactivates [6].  An endurance trained status can be pheno-copied by muscle-specific over-
expression of PGC-1α, even in the absence of physical activity [7; 8; 9]. PGC-1α induces 
mitochondrial biogenesis, improves oxygen supply to muscle by promoting angiogenesis [10], 
increases peak oxygen consumption, and endurance capacity [8]. Moreover, PGC-1α drives 
fiber-type switching from fast, glycolytic towards slow, oxidative fibers [7]. Most 
importantly, PGC-1α promotes lipid and glucose provision and enhances oxidative 
metabolism [3; 11]. 
 
A reduction in metabolic efficiency is associated with insulin resistance in rodents and 
humans [12]. Regular physical activity is thus believed to exert a beneficial effect by 
elevating the metabolic capacity [13]. However, a careful regulation of this process seems 
important since excessive or dysbalanced oxidative metabolism impairs insulin sensitivity 
[14]. For example, acylcarnitines are generated when the amount of lipids fluxed into β–
oxidation exceeds the capacity of the Krebs cycle and/or oxidative phosphorylation 
(OXPHOS) [14]. These detrimental lipid species are subsequently released into the circulation 
and contribute to the development of insulin resistance. Similarly, the proton gradient that 
generates the mitochondrial membrane potential is a potential source of reactive oxygen 
species (ROS), which are also implicated in the etiology of insulin resistance [15]. Currently, 
it is unresolved whether the induction of oxidative metabolism through PGC-1α leads to 
generation of such metabolites in skeletal muscle in mice fed a normal chow diet. 
 
We now investigated the impact of elevated oxidative metabolism driven by PGC-1α on the 
production of acylcarnitines and/or ROS in the extensor digitorum longus (EDL) muscle, on 
whole body glucose homeostasis and on PI3K activity as an early marker of skeletal muscle 
insulin sensitivity. Finally, we describe the molecular mechanisms that fine-tune oxidative 
metabolism and increase metabolic flexibility upon ectopic expression of PGC-1. 
 
 
Materials and Methods 
 
Animals 
Muscle-specific PGC-1α transgenic mice (MPGC-1α TG) [7] and control littermates were 
maintained in a conventional facility with a fixed 12-h light/dark cycle on a commercial pellet 
chow diet and free access to tap water. Studies were performed according to criteria outlined 
for the care and use of laboratory animals and with approval of the Swiss authorities. 
 
RNA extraction and RT-PCR 
Frozen tissues were homogenized under liquid nitrogen and total RNA was isolated using 
Trizol reagent (Invitrogen). RNA concentrations were adjusted and reverse transcription was 
carried out using random hexamer primers (Promega). Real-time PCR analysis (Power SYBR 
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Green Master Mix, Applied Biosystems) was performed using the ABI Prism 7000 Sequence 
Detector. Relative expression levels for each gene of interest were calculated with the Ct 
method and normalized to the expression of the Tata box binding protein (TBP). 
Mitochondrial DNA content was quantified by determining the ratio of mitochondrial 
cytochrome c oxidase 2 (Cox2) to nuclear intron of β-globin by RT–PCR of isolated DNA.  
 
Lipid oxidation  
Palmitate oxidation was measured as described by Dyck et al [16]. Radioactivity in the water 
phase was quantified using a Beckman liquid scintillation counter. 
All values were corrected for initial tissue weight and expressed as fold change compared to 
control animals. 
 
Muscle ROS 
To monitor intracellular generation of ROS, 2′,7′-dichlorofluorescein diacetate (H2DCFDA) 
(Sigma) was used. EDL muscles were harvested in cold-buffered medium (5 mmol/l HEPES 
in PBS) and immediately frozen in liquid nitrogen. After rapid thawing, medium was 
discarded. Samples were exposed to 8 μmol/l H2DCFDA dissolved in 400 μl fresh medium 
and were incubated at 37°C for 30 min under agitation. Medium was then removed, samples 
were homogenized and further incubated in lysis buffer (0.1% SDS, Tris-HCl, pH 7.4). 
Samples were centrifuged at 14’000rpm. Supernatants were collected and subjected to 
fluorescence analysis at 520 nm under excitation at 485 nm using a microplate reader. 
Dichlorofluorescein fluorescence corresponds to the ROS production generated during the ex 
vivo sample incubation. 
 
Acylcarnitine determination 
Acylcarnitines were extracted from dried blood spots using methanol containing eight 
isotopically labeled internal standards (Cambridge Isotopes Laboratories) and analyzed 
without prior sample derivatization. Precursor ions of m/z 85 in the mass range of m/z 150 to 
450 are acquired on a PerkinElmer API 365 LC-ESI-MS/MS instrument. 
 
Glucose and insulin tolerance tests 
Animals were fasted for 16 h and 6 h before i.p. injection of 2 g/kg glucose and 0.8 U/kg 
insulin, respectively. Blood was obtained at intervals of 15 minutes from the tail vein, and 
glucose levels were determined using a standard glucometer. 
 
PI3K activity 
Muscles were dissected, immediately frozen in liquid nitrogen and homogenized under liquid 
nitrogen. IRS-1 associated PI3K activity was assessed as previously described [17; 18]. 
 
Mitochondrial mass and membrane potential  
Myoblasts isolated from MPGC-1α TG mice and control littermates were permitted to fuse 
into multinucleated myotubes. Mitochondrial mass and membrane potential were measured in 
myotubes using Mitotracker Green (MTG; Molecular Probes) and Tetramethylrhodamine 
ethyl ester (TMRE; Molecular Probes). In brief, cells were incubated with differentiation 
media containing 100nM MTG or 100 nM TMRE for 20 min at 37°C in a humidified 
atmosphere of 5% CO2. After 20 min, cells were washed three times with PBS, and a 
microplate reader was used to measure MTG or TMRE fluorescence (excitation 490 or 549 
nm, emission 516 or 574 nm, respectively). Fluorescent values for the mitochondrial 
membrane potential were corrected for mitochondrial mass. 
 
Data analysis and statistics 
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All data are presented as means ± SE. The data were analyzed by 2-tailed, unpaired Student’s 
t test or Mann-Whitney test when the difference between the two SDs was significantly 
different. Levels of significance are indicated as follows: *** p<0.001, ** p< 0.01, * p< 0.05. 
 
 
Results 
 
Increased mitochondrial biogenesis and elevated mitochondrial DNA content in EDL 
muscle of MPGC-1α TG mice 
PGC-1α gene expression in EDL muscle is ~9 times higher in MPGC-1α TG mice than in 
controls (P < 0.001) and no potentially compensatory changes in the expression of PGC-1β or 
PGC-1-related coactivator are observed (Figure 1A). Consequently, mRNA levels of the 
mitochondrial regulators estrogen-related receptor α and mitochondrial transcription factor A 
as well as the mitochondrial proteins NADH-ubiquinone oxidoreductase Fe-S protein 1, 
NADH-ubiquinone oxidoreductase flavoprotein 2, cytochrome c and medium chain acyl-coA 
dehydrogenase are significantly increased in transgenic animals (Figure 1B). Furthermore, 
MPGC-1α TG mice display elevated mitochondrial DNA content (+64% (P<0.001)) (Figure 
1C) and increased mitochondrial mass (Figure 1D). 
  
Enhanced lipid oxidation is in balance with the Krebs cycle in MPGC-1α TG mice 
We next examined whether these mice subsequently show altered mitochondrial lipid 
metabolism in EDL. Expression of genes involved in the activation of fatty acid β-oxidation 
(CPT-1b and MCD) are up-regulated in MPGC-1α TG mice (+237% and +169% 
respectively); reaching statistical significance only for CPT-1b (P<0.01) (Figure 2A). 
Surprisingly, ACC2, which is implicated in the inhibition of β-oxidation, is similarly induced 
(+189%, P<0.01) (Figure 2A). Nevertheless, the overall β-oxidation rate is increased in 
MPGC-1α TG mice by +62% (P<0.05) (Figure 2B). To evaluate downstream events of lipid 
oxidation, we determined mRNA expression of citrate synthase. Our results show that mRNA 
levels of citrate synthase are significantly higher in MPGC-1α TG mice than in controls 
(+299%, P<0.001) (Figure 2C). 
Excessive or dysbalanced lipid oxidation contributes to skeletal muscle insulin resistance by 
increasing acylcarnitines production and secretion [14]. We thus tested whether the elevated 
lipid oxidation in MPGC-1α TG mice is associated with the production of such detrimental 
metabolites by LC-ESI-MS/MS. This technique is very sensitive and even enables the 
detection of mild defects in lipid oxidation. No significant changes between MPGC-1α TG 
and control animals were found for any of these carnitine esters in the circulation (Figure 2D). 
 
Elevated oxidative phosphorylation, but unchanged ROS generation in MPGC-1α TG mice 
Increased fatty acid oxidation and Krebs cycle activity ultimately feed into the mitochondrial 
oxidative phosphorylation (OXPHOS) for ATP production. Accordingly, genes encoding 
different subunits of the OXPHOS system are elevated in MPGC-1α TG animals (Figure 3A). 
Interestingly, expression of the uncoupling protein 3 (UCP3) is likewise increased (Figure 
3A). UCP3 might dissipate the proton gradient in the mitochondria and thereby reduce the 
membrane potential and ATP synthesis. However, the net effect of these seemingly 
counteracting processes is an increase in membrane potential by +4% (P<0.05) (Figure 3B). 
 
To study the impact of an elevated membrane potential on ROS production, we evaluated 
mRNA expression of genes implicated in ROS production and detoxification. Mitochondrial-
encoded superoxide dismutase 2 (SOD2) is increased in MPGC-1α TG mice (+127%, 
P<0.01), whereas nuclear-encoded SOD1 is decreased by -27% (P<0.05) (Figure 3C). 
Furthermore, the expression of genes involved in H2O2 detoxification, namely catalase, 
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glutathione reductase and glutathione peroxidase, does not differ between MPGC-1α TG and 
control mice (Figure 3C). As a consequence, overall H2O2 production is unaltered in MPGC-
1α TG mice suggesting a tightly regulated balance between OXPHOS and ROS metabolism 
(Figure 3D). 
 
Normal glucose homeostasis despite enhanced muscle oxidative metabolism in MPGC-1α 
TG mice 
The ability of MPGC-1α TG and control mice to deal with an acute glucose load was assessed 
by a glucose tolerance test. Both genotypes show similar glucose excursion curves (Figure 
4A). Insulin tolerance tests were used to determine whether systemic insulin sensitivity is 
altered in MPGC-1α TG mice. The capacities of MPGC-1α TG and control mice to regulate 
blood glucose levels after a bolus of insulin are indistinguishable (Figure 4B). Finally, IRS-1 
associated PI3K activity, which is a very early marker for defects in glucose homeostasis, 
does not differ significantly between the two genotypes (Figure 4C). 
 
 
Discussion 
 
The increasing prevalence of metabolic disorders poses a major public health problem [1] and 
a sedentary lifestyle strongly promotes the development of such metabolic diseases [2]. 
Although most people are aware of the necessity of adequate physical activity, many are 
unable or unwilling to achieve the level that is required to elicit health benefits. The 
development of drugs that mimic the plastic changes elicited by exercise thus constitutes an 
intriguing pharmacological approach to this problem [13; 19]. PGC-1α is an attractive target 
for such interventions because this protein is central to endurance exercise adaptation and by 
itself is sufficient to induce a trained phenotype along with an elevated metabolic capacity [3; 
4; 5; 13]. Moreover, known experimental “exercise mimetics”, including activators for AMP-
dependent protein kinase, at least in part act through PGC-1α [20]. Importantly however, 
when oxidative metabolism is promoted in excess, or when only individual oxidative 
pathways are increased without simultaneous up-regulation of subsequent steps, adverse 
effects on metabolic functions occur [14; 15].  
 
We now show that PGC-1α coordinately induces genes that promote lipid oxidation (CPT-1b 
and MCD), Krebs cycle (citrate synthase) and OXPHOS (subunits of complexes I-V) and 
thereby couples all major oxidative steps in EDL muscle. Intriguingly, we found that PGC-1α 
not only controls the expression of positive, but also of negative regulators of fatty acid 
oxidation and OXPHOS. Thus, the levels of ACC2, an inhibitior of lipid oxidation, and of 
UCP3, which uncouples mitochondria and thereby reduces OXPHOS, are both elevated in the 
transgenic animals. Importantly, while the overall gene expression pattern is ambiguous, the 
net rates are nonetheless clearly showing an increased oxidation of fatty acids and an elevated 
mitochondrial membrane potential. Therefore, our findings imply that the increased β-
oxidation and the subsequent Krebs cycle and OXPHOS are tightly regulated and balanced by 
PGC-1α in EDL muscle (Figure 4D). The concomitant induction of both positive and negative 
regulators of fatty acid oxidation and OXPHOS through PGC-1α boosts metabolic flexibility 
and restrains excessive oxidation. 
 
As a consequence of the complex gene expression controlled by PGC-1α, detrimental side 
products of β-oxidation or increased ROS, which both have been linked to the etiology of 
insulin resistance [14; 15], are not observed in our animal model with ectopically expressed 
PGC-1α in muscle despite significantly higher oxidative activity. A relationship between 
acylcarnitines and insulin resistance has recently been established in rodents and type 2 
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diabetic patients [14; 21; 22]. Elevated acylcarnitines were reported in blood and skeletal 
muscle from insulin-resistant rats, but there was no increase observed in the liver, suggesting 
that blood acylcarnitines mainly originated from muscle [14]. In the human study, long, short- 
and medium-chain acylcarnitines increased in diabetic patients compared to lean individuals 
[21]. The accumulation of short-chain acylcarnitines, which represent late degradation 
products of lipid catabolism, is suggestive of inefficient fatty acid oxidation or poor coupling 
between lipid oxidation and OXPHOS in diabetic subjects [21]. The acylcarnitine profile in 
our study does not reveal any chain-length dependent alterations between wild-type and 
transgenic animals. We even observe a trend towards lower levels of short-chain 
acylcarnitines. This is consistent with an improved oxidative capacity and tight coupling of β-
oxidation, Krebs cycle and OXPHOS. Even when further subdivided into different lipid 
classes, such as saturated, mono- or polyunsaturated acylcarnitines, no differences between 
control and transgenic animals are detectable. This detailed inspection might be important, as 
analogous to fatty acids, saturated species of acylcarnitines might exert a more detrimental 
effect on insulin sensitivity than mono- or polyunsaturated species. The exact connection 
between acylcarnitines and insulin sensitivity is a future issue that needs to be addressed. A 
possible mechanism might involve the induction of NFκB through acycarnitines as previously 
demonstrated in vitro [23].  
Finally, while an effect of PGC-1α on ROS detoxification and mitochondrial uncoupling has 
been shown in previous studies in vitro [24; 25], we now for the first time demonstrate 
unchanged levels of ROS in muscle of PGC-1α transgenic mice compared to wild-type 
controls. These findings suggest a tight balance between mitochondrial activity, a major 
source of ROS, and ROS detoxification in muscle with elevated PGC-1α. This balance might 
be achieved by limited production of ROS via UCP3-mediated mitochondrial uncoupling in 
combination with enhanced ROS detoxification, e.g. through elevated SOD2.  
 
Although we focused our studies on EDL muscle, PGC-1α is obviously elevated in all skeletal 
muscles in our experimental mouse model. Interestingly, the enhancement of muscle 
oxidative metabolism in skeletal muscle does not influence whole body glucose homoeostasis 
as glucose and insulin tolerance remain normal in the transgenic mice fed a normal chow diet. 
The possibility arises, however, that alterations in insulin sensitivity occur in skeletal muscle, 
but that compensatory mechanisms in other tissues restore whole body glucose homeostasis. 
Thus, to directly determine insulin sensitivity in skeletal muscle, PI3K, a key molecule in 
insulin signaling and an early marker for insulin resistance, was investigated as PI3K activity 
is already impaired in the pre-diabetic state [17]. We demonstrate that PI3K activity in EDL 
muscle is similar in wild type and transgenic animals, corroborating further that peripheral 
insulin sensitivity in skeletal muscle is preserved. Intriguingly, sedentary PGC-1 muscle-
specific transgenic mice on a high fat diet develop insulin resistance even faster than wild-
type control mice [26]. We have previously demonstrated that as part of the exercise 
adaptations controlled by PGC-1α, these mice have higher de-novo lipogenesis rates and thus 
exhibit an accumulation of intramyocellular lipids [11]. These data suggested that the use of 
putative exercise mimetics in sedentary individuals on a Western diet could even exacerbate 
pathological conditions. Our findings reported here show that without excess dietary lipids, 
ectopically expressed PGC-1α mediates beneficial adaptations in skeletal muscle, even in 
sedentary mice. 
 
Taken together, our findings provide new insights into the molecular mechanisms by which 
PGC-1α coordinates oxidative metabolism. By tightly balancing lipid oxidation and 
mitochondrial electron transport, elevated muscle PGC-1α avoids the generation of 
detrimental side products that impair insulin sensitivity in mice fed a regular chow diet. Our 
findings imply that while induction of PGC-1α per se does not improve insulin sensitivity in 
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this experimental context, this transcriptional coactivator increases the metabolic flexibility of 
skeletal muscle. 
 
Acknowledgements 
 
We thank Urs A. Meyer (Biozentrum, Basel) and our colleagues in the laboratory for 
discussions and comments on the manuscript. This project was funded by the Swiss National 
Science Foundation, the Muscular Dystrophy Association USA (MDA), the SwissLife 
‘Jubiläumsstiftung für Volksgesundheit und medizinische Forschung’, the Swiss Society for 
Research on Muscle Diseases (SSEM), the Swiss Diabetes Association, the Roche Research 
Foundation, the United Mitochondrial Disease Foundation (UMDF), the Association 
Française contre les Myopathies (AFM), the Gebert-Rüf Stiftung (GRS) and the University of 
Basel. 
 
Conflict of interest: The authors have no conflict of interest. 
 
 
References 
 
[1] S. Crunkhorn, and M.E. Patti, Links between thyroid hormone action, oxidative 
metabolism, and diabetes risk? Thyroid 18 (2008) 227-37. 
[2] F.W. Booth, M.J. Laye, S.J. Lees, R.S. Rector, and J.P. Thyfault, Reduced physical 
activity and risk of chronic disease: the biology behind the consequences. Eur J Appl 
Physiol 102 (2008) 381-90. 
[3] C. Handschin, and B.M. Spiegelman, Peroxisome proliferator-activated receptor gamma 
coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev 27 
(2006) 728-35. 
[4] J. Lin, C. Handschin, and B.M. Spiegelman, Metabolic control through the PGC-1 family 
of transcription coactivators. Cell Metab 1 (2005) 361-70. 
[5] C. Handschin, and B.M. Spiegelman, The role of exercise and PGC1alpha in inflammation 
and chronic disease. Nature 454 (2008) 463-9. 
[6] B.N. Finck, and D.P. Kelly, PGC-1 coactivators: inducible regulators of energy 
metabolism in health and disease. J Clin Invest 116 (2006) 615-22. 
[7] J. Lin, H. Wu, P.T. Tarr, C.Y. Zhang, Z. Wu, O. Boss, L.F. Michael, P. Puigserver, E. 
Isotani, E.N. Olson, B.B. Lowell, R. Bassel-Duby, and B.M. Spiegelman, 
Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle 
fibres. Nature 418 (2002) 797-801. 
[8] J.A. Calvo, T.G. Daniels, X. Wang, A. Paul, J. Lin, B.M. Spiegelman, S.C. Stevenson, and 
S.M. Rangwala, Muscle-specific expression of PPARgamma coactivator-1alpha 
improves exercise performance and increases peak oxygen uptake. J Appl Physiol 104 
(2008) 1304-12. 
[9] M. Sandri, J. Lin, C. Handschin, W. Yang, Z.P. Arany, S.H. Lecker, A.L. Goldberg, and 
B.M. Spiegelman, PGC-1alpha protects skeletal muscle from atrophy by suppressing 
FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci U S A 103 
(2006) 16260-5. 
[10] Z. Arany, S.Y. Foo, Y. Ma, J.L. Ruas, A. Bommi-Reddy, G. Girnun, M. Cooper, D. 
Laznik, J. Chinsomboon, S.M. Rangwala, K.H. Baek, A. Rosenzweig, and B.M. 
Spiegelman, HIF-independent regulation of VEGF and angiogenesis by the 
transcriptional coactivator PGC-1alpha. Nature 451 (2008) 1008-12. 
[11] S. Summermatter, O. Baum, G. Santos, H. Hoppeler, and C. Handschin, Peroxisome 
proliferator-activated receptor {gamma} coactivator 1{alpha} (PGC-1{alpha}) 
 - 10 - 
promotes skeletal muscle lipid refueling in vivo by activating de novo lipogenesis and 
the pentose phosphate pathway. J Biol Chem 285 (2010) 32793-800. 
[12] A.E. Civitarese, and E. Ravussin, Mitochondrial energetics and insulin resistance. 
Endocrinology 149 (2008) 950-4. 
[13] A.P. Russell, PGC-1alpha and exercise: important partners in combating insulin 
resistance. Curr Diabetes Rev 1 (2005) 175-81. 
[14] T.R. Koves, J.R. Ussher, R.C. Noland, D. Slentz, M. Mosedale, O. Ilkayeva, J. Bain, R. 
Stevens, J.R. Dyck, C.B. Newgard, G.D. Lopaschuk, and D.M. Muoio, Mitochondrial 
overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin 
resistance. Cell Metab 7 (2008) 45-56. 
[15] N. Houstis, E.D. Rosen, and E.S. Lander, Reactive oxygen species have a causal role in 
multiple forms of insulin resistance. Nature 440 (2006) 944-8. 
[16] D.J. Dyck, S.J. Peters, J. Glatz, J. Gorski, H. Keizer, B. Kiens, S. Liu, E.A. Richter, L.L. 
Spriet, G.J. van der Vusse, and A. Bonen, Functional differences in lipid metabolism 
in resting skeletal muscle of various fiber types. Am J Physiol 272 (1997) E340-51. 
[17] S. Summermatter, D. Mainieri, A.P. Russell, J. Seydoux, J.P. Montani, A. Buchala, G. 
Solinas, and A.G. Dulloo, Thrifty metabolism that favors fat storage after caloric 
restriction: a role for skeletal muscle phosphatidylinositol-3-kinase activity and AMP-
activated protein kinase. Faseb J 22 (2008) 774-85. 
[18] S. Summermatter, H. Marcelino, D. Arsenijevic, A. Buchala, O. Aprikian, F. 
Assimacopoulos-Jeannet, J. Seydoux, J.P. Montani, G. Solinas, and A.G. Dulloo, 
Adipose tissue plasticity during catch-up fat driven by thrifty metabolism: relevance 
for muscle-adipose glucose redistribution during catch-up growth. Diabetes 58 (2009) 
2228-37. 
[19] V.A. Narkar, M. Downes, R.T. Yu, E. Embler, Y.X. Wang, E. Banayo, M.M. Mihaylova, 
M.C. Nelson, Y. Zou, H. Juguilon, H. Kang, R.J. Shaw, and R.M. Evans, AMPK and 
PPARdelta agonists are exercise mimetics. Cell 134 (2008) 405-15. 
[20] A.L. Carey, and B.A. Kingwell, Novel pharmacological approaches to combat obesity 
and insulin resistance: targeting skeletal muscle with 'exercise mimetics'. Diabetologia 
52 (2009) 2015-26. 
[21] S.J. Mihalik, B.H. Goodpaster, D.E. Kelley, D.H. Chace, J. Vockley, F.G. Toledo, and 
J.P. DeLany, Increased levels of plasma acylcarnitines in obesity and type 2 diabetes 
and identification of a marker of glucolipotoxicity. Obesity (Silver Spring) 18 (2010) 
1695-700. 
[22] J. An, D.M. Muoio, M. Shiota, Y. Fujimoto, G.W. Cline, G.I. Shulman, T.R. Koves, R. 
Stevens, D. Millington, and C.B. Newgard, Hepatic expression of malonyl-CoA 
decarboxylase reverses muscle, liver and whole-animal insulin resistance. Nat Med 10 
(2004) 268-74. 
[23] S.H. Adams, C.L. Hoppel, K.H. Lok, L. Zhao, S.W. Wong, P.E. Minkler, D.H. Hwang, 
J.W. Newman, and W.T. Garvey, Plasma acylcarnitine profiles suggest incomplete 
long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in 
type 2 diabetic African-American women. J Nutr 139 (2009) 1073-81. 
[24] J. St-Pierre, J. Lin, S. Krauss, P.T. Tarr, R. Yang, C.B. Newgard, and B.M. Spiegelman, 
Bioenergetic analysis of peroxisome proliferator-activated receptor gamma 
coactivators 1alpha and 1beta (PGC-1alpha and PGC-1beta) in muscle cells. J Biol 
Chem 278 (2003) 26597-603. 
[25] J. St-Pierre, S. Drori, M. Uldry, J.M. Silvaggi, J. Rhee, S. Jager, C. Handschin, K. Zheng, 
J. Lin, W. Yang, D.K. Simon, R. Bachoo, and B.M. Spiegelman, Suppression of 
reactive oxygen species and neurodegeneration by the PGC-1 transcriptional 
coactivators. Cell 127 (2006) 397-408. 
 - 11 - 
[26] C.S. Choi, D.E. Befroy, R. Codella, S. Kim, R.M. Reznick, Y.J. Hwang, Z.X. Liu, H.Y. 
Lee, A. Distefano, V.T. Samuel, D. Zhang, G.W. Cline, C. Handschin, J. Lin, K.F. 
Petersen, B.M. Spiegelman, and G.I. Shulman, Paradoxical effects of increased 
expression of PGC-1alpha on muscle mitochondrial function and insulin-stimulated 
muscle glucose metabolism. Proc Natl Acad Sci U S A 105 (2008) 19926-31. 
 
  
Figure Legends 
 
Figure 1. Effect of PGC-1α on mitochondrial gene expression and biogenesis in EDL.  
(A and B) Relative gene expression of PGC-1α, PGC-1β and PRC (A) and mitochondrial 
target genes (B) was measured by RT-PCR and expressed as fold change over controls. 
Abbreviations: PGC-1, peroxisome proliferator-activated receptor γ coactivator 1; PRC, PGC-
1-related coactivator; ERRα, estrogen-related receptor α; TFAM, mitochondrial transcription 
factor A; Ndufs1, NADH-ubiquinone oxidoreductase Fe-S protein 1; Ndufv2, NADH-
ubiquinone oxidoreductase flavoprotein 2; Cycs, cytochrome c;  MCAD, medium-chain acyl-
coenzyme A (CoA) dehydrogenase. 
(C) Mitochondrial DNA content determined from the ratio of mitochondrial cytochrome c 
oxidase 2 (Cox2) to nuclear intron of β-globin.  
(D) Mitochondrial mass determined by Mitotracker green.  
All values are means ±SE (n = 8 per group); * p<0.05; ** p<0.01; *** p<0.001, as assessed 
by student’s t test. 
 
Figure 2. Lipid oxidation in EDL muscle of MPGC-1α TG mice vs. control animals.  
(A) Relative expression of genes regulating lipid oxidation was measured by RT-PCR and 
expressed as fold change over controls. Abbreviations: CPT-1b, carnitine palmitoyl 
transferase 1b; MCD, malonyl CoA decarboxylase; ACC2, acetyl CoA carboxylase 2. 
(B) Palmitate oxidation was assessed ex vivo using tritiated palmitate.  
(C) Relative gene expression of citrate synthase as a marker of mitochondrial activity was 
measured by RT-PCR.  
(D) Blood profile of acylcarnitine species was determined using tandem mass spectroscopy 
and clustered according to saturated (SFA), mono- and polyunsaturated acylcarnitines 
(MUFA and PUFA respectively).  
All values are expressed as means ±SE (n =6-8 per group); * p<0.05; ** p<0.01; *** p<0.001. 
 
Figure 3. Oxidative phosphorylation in EDL muscle of MPGC-1α TG mice vs. control 
animals.  
(A) Relative expression of genes involved in oxidative phosphorylation and uncoupling was 
measured by RT-PCR and expressed as fold change over controls. Complex I (Ndufb5, 
NADH dehydrogenase (ubiquinone) 1 β subcomplex 5); Complex II (SDHB, succinate 
dehydrogenase complex II, subunit B); Complex III (UQCRC, ubiquinol-cytochrome c 
reductase complex core); Complex IV (Cox5b, cytochrome c oxidase, subunit Vb); Complex 
V (Atp50, ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit); UCP3, 
uncoupling protein 3. 
(B) Membrane potential was assessed in mouse myotubes in vitro.  
(C) Relative gene expression for genes involved in H2O2 production and detoxification; SOD, 
superoxide dismutase; CAT, catalase; GPX, glutathione peroxidase; GR, glutathione 
reductase.  
(D) Measurement of H2O2 in EDL muscle of MPGC-1α TG mice vs. control animals. 
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Figure 4. Whole body glucose homeostasis and skeletal muscle insulin sensitivity in 
MPGC-1α TG mice vs. control animals.  
(A and B) Glucose (A) and Insulin (B) tolerance tests in MPGC-1α TG mice and control 
animals.  
(C) IRS-1 associated PI3K activity in skeletal muscle.  
All values are expressed as means ±SE (n =6-8 per group); * p<0.05; ** p<0.01. 
(D) Model integrating the findings of the study. PGC-1α simultaneously acts on lipid 
oxidation, Krebs cycle and electron transport chain and thus couples all major oxidative 
pathways. Concomitantly, PGC-1α promotes the transcription of positive and negative 
regulators of lipid oxidation and electron transport chain. Thereby PGC-1α balances oxidative 
metabolism. Subsequently, excessive metabolism and the generation of acylcarnitines and 
ROS are prevented. 
Abbreviations: CPT-1b, carnitine palmitoyl transferase 1b; MCD, malonyl CoA 
decarboxylase; ACC2, acetyl CoA carboxylase 2; I-V, complexes I-V; UCP3, uncoupling 
protein 3; ROS, reactive oxygen species. 
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